Cancer is solved: by PD-1/PDL-1 inhibitors

Improper title.

1. This is specifically about non-SCLC.

2. This article is entirely about a downside to receiving PD-1/PDL-1 inhibitor biologics as immunotherapy; that approximately a third of patients develop HPD and should be switched to salvage chemotherapy as soon as this is noted.